The investigators expect to better characterise B cell subpopulation and functional properties early after graft, to analyse effect of induction therapy (thymoglobulin versus basiliximab) on B cells, and to compare this B cell profiles with those obtained in our previous study in patients with chronic Antibody Mediated Rejection (cAMR)
Study Type
OBSERVATIONAL
Enrollment
40
The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
CHU Brest
Brest, France
RECRUITINGTours University Hospital
Tours, France
RECRUITINGThe distribution of mature blood B cells subpopulations will be compared between the 2 groups
Time frame: one year after renal transplant
Proliferation of freshly isolated cells T in presence of autologous B cells will be compared between the 2 groups.
Time frame: one year after renal transplant
Serum B-cell activating factor (BAFF) concentration comparison between the two groups
Time frame: one year after renal transplant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.